Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron GlobeNewswire January 12, 2022 Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron WALTHAM, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc.,...
Tillman Gerngross Dan Budwick Monique Allaire Laura Walker Strategic Communications Adagio Therapeutics Inc
Source: asiaone.com